Effect of imatinib mesylate in a patient with a metastatic gastrointestinal stromal tumor with a c-kit mutation in exon 11.
Kubota
Keisuke
K
Department of Surgery, The International University of Health and Welfare Mita Hospital, Mita, Tokyo, Japan. kubota@iuhw.ac.jp
Katayama
Atom
A
Takeshita
Yutarou
Y
Nozaki
Koji
K
Ueda
Tetsuya
T
Imamura
Kazuhiro
K
Hiki
Naoki
N
Nomura
Sachiyo
S
Kaminishi
Michio
M
Mafune
Ken-Ichi
K
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D005091:Exons; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics*; D011743:Pyrimidines / Q000627:therapeutic use*; D017384:Sequence Deletion
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit